Oncolytics Biotech Receives FDA's Fast Track Designation To Pelareorep In Combination With A Checkpoint Inhibitor Treat Squamous Cell Carcinoma Of Anal Canal
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration ("FDA") has granted
Oncolytics Biotech got special fast-track approval from the FDA to test a new cancer medicine faster than usual. This shows the FDA thinks the treatment could be important, which is a good sign that doctors and the company are on a promising path.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.